3
Clinical Trials associated with NWRD-08评价NWRD08在HPV16/18阳性宫颈HSIL患者中的安全性和耐受性的 I 期临床研究
[Translation] A Phase I clinical study to evaluate the safety and tolerability of NWRD08 in patients with HPV16/18-positive cervical HSIL
评估NWRD08在宫颈HPV16和/或HPV18阳性HSIL患者中的安全性、耐受性和免疫原性
[Translation] To evaluate the safety, tolerability and immunogenicity of NWRD08 in patients with cervical HPV16 and/or HPV18 positive HSIL
Phase I Safety and Tolerability Study of NWRD08 in HPV-16 and/or HPV-18 Related Cervical High-grade Squamous Intraepithelial Lesion (HSIL) Patients
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL.
Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive
This is an open-label exploratory clinical study. The main objective is to explore the immunogenicity of HPV therapeutic DNA vaccine NWRD08.
100 Clinical Results associated with NWRD-08
100 Translational Medicine associated with NWRD-08
100 Patents (Medical) associated with NWRD-08
100 Deals associated with NWRD-08